Sanofi-aventis Announces 2007 Earnings Ahead of Guidance Sharp Rise in Propose...(he U.S. dollar. Changes in Group structu...),Health

2007 full-year net sales rose by 2.8% to euro 28,052 million. Exchange rate movements had an unfavorable effect of 3.8 points. Changes in Group structure had an unfavorable effect of 0.1 of a point over the year as a whole. After taking account of these effects, net sales fell by 1.1% on a reported basis.

The group net sales consist of sales of pharmaceuticals division (90.1%) and sales of vaccines division (9.9% versus 8.9% in 2006)

Net sales by division - Pharmaceuticals

Fourth-quarter net sales for the pharmaceuticals business were euro 6,262 million, down 0.6%. Net sales of the top 15 products were down 0.3% at euro 4,174 million, representing 66.7% of pharmaceuticals net sales against 66.5% for the comparable period of 2006.

Excluding the impact of the introduction of generics(4) of Ambien(R) IR in the United States and Eloxatin(R) in Europe, the top 15 products would have recorded growth of 9.5%.

Over 2007 as a whole, net sales for the pharmaceuticals business were up 1.7% at euro 25,274 million. Net sales of the top 15 products rose by 3.2% to euro 17,071 million, representing 67.5% of pharmaceuticals net sales against 66.5% in 2006. Excluding the impact of the introduction of generics(4) of Ambien(R) IR in the United States and Eloxatin(R) in Europe, the top 15 products would have recorded growth of 10.7% in 2007.

Change on a Change on a

Q4 2007 comparable FY 2007 comparable

euro million net sales basis net sales basis

Lovenox(R) 674 +17.4% 2,612 +13.4%

Plavix(R) 609 +14.0% 2,424 +9.5%

Lantus(R)
'/>"/>